Gilead Sciences, Inc. balance sheet
At the end of its fiscal year on Dec 31, 2025, Gilead Sciences, Inc. reported total assets of $59.02B and shareholders' equity of $22.70B. That works out to a current ratio of 1.55 (current assets ÷ current liabilities), long-term debt of 0.97× shareholders' equity.
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $56.98B | $70.28B | $63.67B | $61.63B | $68.41B | $67.95B | $63.17B | $62.12B | $58.99B | $59.02B |
| Current assets | $19.59B | $31.82B | $35.84B | $30.30B | $16.00B | $14.77B | $14.44B | $16.09B | $19.17B | $18.34B |
| Cash & equivalents | $8.23B | $7.59B | $17.94B | $11.63B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B |
| Current liabilities | $9.22B | $11.63B | $10.61B | $9.76B | $11.40B | $11.61B | $11.24B | $11.28B | $12.00B | $11.81B |
| Long-term debt | $26.35B | $30.80B | $24.57B | $22.09B | $28.64B | $25.18B | $22.96B | $23.19B | $24.90B | $22.13B |
| Shareholders' equity | $18.89B | $20.44B | $21.39B | $22.52B | $18.20B | $21.07B | $21.24B | $22.83B | $19.33B | $22.70B |
| Reported in | 10-K 2018 | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 882095 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.